Simulation of Chemotherapy Effects in Older Breast Cancer Patients With High Recurrence Scores.
Tumor genomic expression profile (GEP) data is used to guide chemotherapy choice, but there are gaps in evidence for women 65+. We estimate chemotherapy effects by age and comorbidity-level among women with early stage, hormone-receptor+/HER2- breast cancers and Oncotype DX scores of 26+. A discrete-time stochastic state-transition simulation model synthesized data from population studies and clinical trials to estimate outcomes over a 25-year horizon for subgroups based on age (65-69, 70-74, 75-79, 80-89y) and comorbidity-levels (no/low, moderate, severe). Outcomes were discounted at 3%, and included quality-adjusted life years (QALYs), life years, and breast cancer and other-cause mortality with chemo-endocrine vs. endocrine therapy. Sensitivity analysis tested the impact of varying uncertain parameters. Women ages 65-69y with no/low comorbidity gained 0.16 QALYs with chemo-endocrine and reduced breast cancer mortality from 34.8% to 29.7%, for an absolute difference of 5.1%; this benefit was associated with a 12.8% rate of grade 3/4 toxicity. Women ages 65-69y with no/low or moderate comorbidity levels, and women aged 70-74 with no/low comorbidity had small chemotherapy benefits. All women ages 75+ experienced net losses in QALYs with chemo-endocrine therapy. The results were robust in sensitivity analyses. Chemotherapy had greater benefits as treatment effectiveness increased, but toxicity reduced the QALYs gained. Among women ages 65-89 whose tumors indicate a high recurrence risk, only those age 65-74y with no/low or moderate comorbidity have small benefits from adding chemotherapy to endocrine therapy. GEP testing (and chemotherapy use) should be reserved for women under age 75y without severe comorbidity.